

Biographical sketch and personal statement updated March 2022

Lawrence B. Faulkner, M.D.

Pediatric Hematologist-Oncologist
Bone Marrow Transplant Specialist

Medical Coordinator
Cure2Children Foundation, Florence-Italy
Mobile [+39 3355621861](tel:+393355621861) and [+91 7483924238](tel:+917483924238)
lawrence.faulkner@cure2children.org



Education

Medical Doctor Degree: University of Florence, Italy, 1983 (110/110 cum laude).

Pediatric Residency: Long Island College Hospital, Brooklyn NY, 1986-89.

Pediatric Hematology-Oncology Fellowship: Memorial Sloan Kettering Cancer Center - New York Hospital, New York NY, Cornell University Medical School combined program, 1989-92.

International memberships

European Society for Blood and Marrow Transplantation (CIC 0465)

American Society of Hematology

American Society of Clinical Oncology

International Society of Pediatric Oncology

Other qualifications

Chair, Outreach Subcommittee, Pediatric Diseases Working Party, European Society for Blood and Marrow Transplantation

Leader, Thalassemia Group, Cure4Kids (St Jude Children's Research Hospital - USA)

Inspector, JACIE (Joint Accreditation Committee ISCT-EBMT)

Visiting professor at the Yerevan State Medical University - Armenia

Work experience

1990-1992 Pediatric Fellow in the laboratory of Developmental Hematology directed by Malcolm A. S. Moore Ph.D., Memorial Sloan Kettering Cancer Center, NY, USA.

1992-1993 Pediatric Hematology-Oncology attending at the Catholic University Medical Center (Policlinico Gemelli) in Rome, Italy.

1994-2005 Pediatric Hematology-Oncology attending at the Children's Hospital of Florence (Ospedale Meyer).

2006-present. Medical Coordinator of the Cure2Children Foundation.

2015-2017. Program Director, Sankalp-People Tree Hospitals Bone Marrow Transplant Unit, Bangalore, India.

2017-present Medical Coordinator of the Sankalp India Foundation.

Research Grants and Awards

1995 Principal investigator of a three-year "Seed Grant" by the Italian Cancer Research Association. Total funds: 90,000 Euros.

1997 Principal investigator of a four-year research project by the Italian Neuroblastoma Research Association on minimal residual disease analysis of neuroblastoma. Total funds: 80,000 Euros.

2001 Principal investigator of a four-year research support by the Tommasino Bacciotti Foundation on the use of stem cell transplantation for the cure of high-risk brain tumors and other pediatric malignancies. Total funds: 200,000 Euros.

2002 Coordinator of the Marrow Disease Evaluation Subcommittee of the Neuroblastoma Group of the International Society of Pediatric Oncology (SIOP).

2007 Founder and Advisory Board Coordinator of the Cure2Children Foundation

2008 Principal investigator for a two-year grant from the *Fondazione Monte dei Paschi di Siena*, Italy, to support a network of centers offering the cure for thalassemic children in Pakistan. Total funds: 150,000 Euros.

2010 Principal investigator for a one-year grant from the *Fondazione Monte dei Paschi di Siena*, Italy, on the support for sustainable cure and prevention of thalassemia in India through social entrepreneurship initiatives. Total funds: 20,000 Euros.

2010 Coordinator of a two-year grant for a Global Neuroblastoma Database module within the St Jude's Hospital Outreach Program Pediatric Oncology Network Database by the *Fondazione Umberto Veronesi*, Italy. Total funds: 122,000 Euros.

2010 Coordinator of a four-year grant of 85,000,000 Pakistani rupees (~750,000 Euros) from the Pakistani-Italian Dept-for-development Swap Agreement for a project on the cure and prevention of thalassemia in Pakistan.

2014 - present coordinator of a grant for the consolidation of the Global Neuroblastoma Network by the *Fondazione Umberto Veronesi*, Italy. Total funds: 280,000 Euros.

2017 - present coordinator of a funding and cooperation grant for improving access to blood and marrow transplantation globally. Total funds: 1,200,000 Euros.

2021 - Distinguished Service Award by the Center for International Blood and Marrow Transplant Research (CIBMTR).

2021 - Appointed as visiting professor at the Yerevan State Medical University – Armenia.

Full-text scientific publications

[\(Citation indexes\)](#)

1. Matthey K., Hylton J., Penumarthy N., Khattab M., Soh S.Y., Nguyen H.T.K., Alcasabas A.P., Fawzy M., Saab R., Khan M.S., Ghandour K., Chantada G., Parikh N.S., **Faulkner L.**, Lam C.G., and Howard S.C. 'Global Neuroblastoma Network: An International Multidisciplinary Neuroblastoma Tumor Board for Resource-Limited Countries'. *Pediatric Blood & Cancer*, January 2022. <https://doi.org/10.1002/pbc.29568>.
2. Marwah P., Ramprakash S., Prasad S., TR., Mane Gizhlaryan M., Trivedi D., Shah V., Chitaliya A., Elizabeth S., Agarwal R.K., Dhanya R. and **Faulkner L.** 'Is It Safe and Efficacious to Remove Central Lines in Pediatric Bone Marrow Transplant Patients with Platelets Less than 20,000/ml?' *EJHaem*, January 2022. <https://doi.org/10.1002/jha2.379>.

3. Dhanya R., Agarwal R.K., Ramprakash S., Trivedi D., Shah V., Bhat N., Reddy M., Elizabeth S., Batool A., Khalid S. and **Faulkner L.** ‘Do Weekly Surveillance Cultures Contribute to Antibiotic Stewardship and Correlate with Outcome of HSCT in Children? A Multicenter Real-World Experience of 5 Years from the Indian Subcontinent’. *Transplantation and Cellular Therapy*, December 2021. <https://doi.org/10.1016/j.jtct.2021.12.008>.
4. Diaz-de-Heredia C., Bresters D., **Faulkner L.**, Yesilipek A., Strahm B., Miano M., Dalle,J.-H., Peffault de Latour R., Corbacioglu S., 2021. Recommendations on hematopoietic stem cell transplantation for patients with Diamond–Blackfan anemia. On behalf of the Pediatric Diseases and Severe Aplastic Anemia Working Parties of the EBMT. *Bone Marrow Transplantation* 31 August 2021. <https://doi.org/10.1038/s41409-021-01449-w>
5. Mehta P., Ramprakash S., Raghuram C.P., Trivedi D., Dhanya R-, Agarwal R.K., and **Faulkner L.** Pre-Transplant Donor-Type Red Cell Transfusion Is a Safe and Effective Strategy to Reduce Isohemagglutinin Titers and Prevent Donor Marrow Infusion Reactions in Major ABO-Mismatched Transplants’. *Annals of Hematology*, 19 June 2021. <https://doi.org/10.1007/s00277-021-04571-3>.
6. El Fakih R. , Greinix H., Koh M., ...**Faulkner L.**, ... Aljurf M. Worldwide Network for Blood and Marrow Transplantation (WBMT) Recommendations Regarding Essential Medications Required to Establish an Early Stage Hematopoietic Cell Transplantation Program. *Transplantation and Cellular Therapy*, 21 dicembre 2020. <https://doi.org/10.1016/j.jtct.2020.12.015>.
7. de la Fuente J., Gluckman E., Makani J., Telfer P., **Faulkner L.**, Corbacioglu S., Amrolia P., Ansari M., Balduzzi A., Dalassier A., Dalle J., Hereda Diaz C., Feuchtinger T., Locatelli F., Lucchini G., Galimard J., Gonzalez Vincent M., Handgretinger R., Kleinschmidt K., Lawitschka A., Perez Martinez A., Peters C., Rocha V., Ruggeri A., Sedlacek P., Svec P., Toporski J., Yesilipek A. The role of haematopoietic stem cell transplantation for sickle cell disease in the era of targeted disease-modifying therapies and gene editing- *The Lancet Haematology*, 7 (12):e902-e911, 2020. [https://doi.org/10.1016/S2352-3026\(20\)30283-0](https://doi.org/10.1016/S2352-3026(20)30283-0)
8. Ramprakash S., Agarwal R., Dhanya R., Marwah P., Soni R., Yaqub N., Fatima I., Gooneratne L., Williams S., Khalid S., Sen S. and **Faulkner L.**: Splenomegaly may increase the risk of rejection in low risk matched related donor transplant for thalassemia and this risk can be partially overcome by additional immunosuppression during conditioning. *Biology of Blood and Marrow Transplantation*,26(10):1886-1893, 2020. <https://doi.org/10.1016/j.bbmt.2020.06.013>
9. **Faulkner L.**, Verna M., Rovelli A., Kumar Agarwal R., Dhanya R., Ramprakash S., Raghuram CP, Mehta P., Sandeep Elizabeth S., Khalid S., Batool A., Khan-Ghilani S., Fatima I., Zara T., Marwah P., Soni R., Trivedi D., Conter V., Canesi M., Othman D., Faeq V., Kleinschmidt K., Yesilipek A., Catherine G. Lam C.G., Scott C. Howard S.C. and Corbacioglu S. Setting up and sustaining blood and marrow transplant services for children in Middle-Income Economies: An experience-driven position paper on behalf of the PDWP of the EBMT *Bone Marrow Transplantation*, (2021) 56:536–543. <https://doi.org/10.1038/s41409-020-0983-5>.
10. **Faulkner L.**: Telemedicine in COVID-19 Era: Lessons from Online Co-Management of Bone Marrow Transplant Patients. *Journal of Islamabad Medical & Dental College* 9, n. 2 (2020): 79–81. <https://doi.org/10.35787/jimdc.v9i2.550>.
11. Dhanya R., Agarwal R.K, Sedai A., Kumari A., Parmar L., Hegde S., Gowda A., Gujjal P., Pushpa H, Dasaratha Ramaiah Jinka D.R., Karri, C., Jali S., Tallur N., Shenoy U., Pinto D., Ramprakash S., Raghuram S., Trivedi D., Cao X., and **Faulkner L.** ‘Life expectancy and risk factors for early death in patients with severe thalassemia syndromes in South India’. *Blood Advances* (2020) 4 (7): 1448–1457. doi: 10.1182/bloodadvances.2019000760
12. **Faulkner L.** How to setup a successful transplant program for hemoglobinopathies in developing countries, the Cure2Childre approach. *Hematology/Oncology and Stem Cell Therapy* (2020)13(2):71-75. doi: 10.1016/j.hemonc.2019.12.010.

13. Marwah P. Rajpreet S., Ramprakash S., CP Raghuram, Trivedi D., Agarwal R. K., Dayana R., Sedai A., Kumari A., Parmar L. and **Faulkner L.** The impact of Host vs. Graft mismatches on rejection of haploidentical bone marrow transplants in thalassemia patients using post-transplant cyclophosphamide. *Bone Marrow Transplantation.* (2020) 55:1824–1828. doi:10.1038/s41409-019-0692-0
14. Agarwal, R. K., Sedai A., Kumari A., Parmar L., Dhanya R., Dhimal S., Shriniwas R., Ramprakash, S. and **Faulkner, L.** Information Technology-Assisted Treatment Planning and Performance Assessment for Severe Thalassemia Care in a Resource-Limited Setting. *Journal of Medical Internet Research* 7 (2019): e929,1.
15. **Faulkner, L.** The Rising Global Burden of Hemoglobinopathies, A Challenge and an Opportunity for Health Care in Pakistan. *Journal of Islamabad Medical & Dental College* 7 (2018): 1–4.
16. Parmar, L., Sedai, A., Ankita, K., Dhanya, R., Agarwal, R.K., Dhimal, S., Shriniwas, R., Iyer, H.V., Gowda, A., Gujjal, P., Pushpa, H., Jain, S., Kondaveeti, S., Dasaratha Ramaiah, J., Raviteja, Jali, S., Tallur, N.R., Ramprakash, S., **Faulkner, L.** Can inequity in healthcare be bridged in LMICs – Multicentre experience from thalassemia day care centres in India. *Pediatric Hematology Oncology Journal* 2:88-93, 2017. <https://doi.org/10.1016/j.phoj.2017.12.002>.
17. Agarwal, R.K., Sedai, A., Kumari A., Parmar, L., Dhanya, R., Dhimal, S., Shriniwas, R., Sumithra P, D., Iyer H., D., Gowda, A., Gujjal, D.P., Pradeep R, D., Jain, D.S., Kondaveeti, D.S., Ramaiah, D.J., Raviteja, D., Sharma, D.H., Jali, D.S., Viragi, S., and **Faulkner L.** Multi-institutional, retrospective review of blood transfusion practices and outcomes in a large cohort of thalassemia patients in South India. *Pediatric Hematology Oncology Journal* 2:74-78, 2017. <https://doi.org/10.1016/j.phoj.2017.12.001>.
18. Ramprakash, S., Agarwal, R., Dhanya, R., Marwah, P., Soni, R., Yaqub, N., Fatima, I., Zhara, T., Gooneratne, L., Williams, S., Khalid, S., Sen, S., Kanwar, V. and **Faulkner, L.** Low-cost matched sibling bone marrow transplant for standard-risk thalassemia in a limited-resource setting. *Pediatric Hematology Oncology Journal*, 2:107-113, 2017. <https://doi.org/10.1016/j.phoj.2017.12.002>.
19. Ramprakash, S., Agarwal, R.K., Dhanya, R., Sedai A., Kumari A., Parmar L., Srinivas R., Rao Kakulamari, V., Marwah, P., Soni, R. Williams, S., Rathnayake, W., Sen, S., Tulpule, S., **Faulkner, L.:** Rejection of Paternal vs. Maternal Fully Matched Bone Marrow Grafts in Children with Thalassemia. *Bone Marrow Transplantation* 52(11):1585-1586, 2017.
20. Agarwal, R.K., Kumari, A., Sedai, A., Parmar, L., Dhanya, R., and **Faulkner, L.:** The Case for High Resolution Extended 6-Loci HLA Typing for Identifying Related Donors in the Indian Subcontinent. *Biology of Blood and Marrow Transplantation* 23(9):1592-1596, 2017.
21. **Faulkner, L.,** Uderzo C., Khalid S., Marwah P., Soni R., Yaqub N., Amanat S., Fatima I., Khan Gilani S., Zahra T., Ramprakash S., Gooneratne L., Dissanayake R., Williams S., Rathnayake W., Srinivas R., Sedai A., Kumari A., Parmar L., Dhanya R. and Agarwal R.K.: ATG vs. Thiotepa with Busulfan and Cyclophosphamide in Matched-Related Bone Marrow Transplantation for Thalassemia. *Blood Advances* 1(13):792-901, 2017.
22. Parikh, N.S., Howard S.C., Chantada G., Israels T., Khattab M., Alcasabas P., Lam C.G., **Faulkner L.,** Park JR., London W.B., Matthay K.K.: SIOP-PODC Recommended Graduated Intensity Guidelines for Diagnosis, Risk Stratification and Treatment of Neuroblastoma in Resource-Limited Countries. *Pediatric Blood & Cancer* 62(8):1305-16 (2015),
23. **Faulkner, L.** A global response to a global problem: The rising burden of hemoglobinopathies. *Blood and Cancer Secrets* 2, 7–13 (2014).
24. El Missiry M., Hamed Hussein M, Khalid S., Yaqub N., Khan S., Fatima I., Uderzo C., and **Faulkner L.** Assessment of Serum Zinc Levels of Patients with Thalassemia Compared to Their Siblings. *Anemia* 2014 (August 14, 2014): e125452. doi:10.1155/2014/125452.

25. **Faulkner L.** Hematopoietic Stem Cell Transplantation for Thalassemia, Price and Prejudice. In *Thalassemia: Causes, Treatment Options and Long-Term Health Outcomes*, 71–81. *Recent Advances in Hematology Research*. Makenzie Greene, 2014.
26. Agarwal R.K., Sedai A., Dhinal S., Agarwal A., Clemente L., Siddique S., Yaqub N., Khalid S., Itrat F., Khan A., Gilani, S.K., Marwah P, Soni R., El Missiry M, Hussain M.H., Uderzo C. and **Faulkner L.** A Prospective International Cooperative Information Technology Platform Built Using Open-Source Tools for Improving the Access to and Safety of Bone Marrow Transplantation in Low- and Middle-Income Countries. *Journal of the American Medical Informatics Association: JAMIA* 2014, doi:10.1136/amiajnl-2013-002594.
27. Yaqub N., Khalid S., Fatima I., Khan A., Khan Gilani S., El Missiry M., Hussain M.H., Uderzo C., and **Faulkner L.**: Second Bone Marrow Transplantation for Thalassemia Major Using Post-Transplant Cyclophosphamide. *Bone Marrow Transplantation*, 49:845-846, 2014.
28. **Faulkner L.**, Uderzo C., and Masera G.: International Cooperation for the Cure and Prevention of Severe Hemoglobinopathies. *Journal of Pediatric Hematology/Oncology* 35(6):419-23, 2013.
29. **Faulkner L.** Setting up Bone Marrow Transplantation for Children with Thalassemia May Facilitate Pediatric Cancer Care. *South Asian Journal of Cancer* 2:109-112, 2013.
30. El Missiry M. and **Faulkner L.** Thalassemia, *St Jude Children's Research Hospital, Cure4Kids Oncopedia*, May 2013
31. Mehta, P.A. and **Faulkner L.** Hematopoietic Cell Transplantation for Thalassemia: A Global Perspective. *Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation* 19(1 Suppl) 2013: S70–3, 2013.
32. Hussein, M.H., El Missiry M., Khalid S., Yaqub N., Khan Gilani S., Fatima I., Zara T., Marwah P., Soni, R., Bernard F., Manna N., Uderzo C. and **Faulkner L.**: Bone Marrow Transplantation for Thalassemia: a Global Perspective. *Thalassemia Reports* 3:103–107, 2013. doi:10.4081/thal.2013.s1.e42.
33. **Faulkner L.**, Yaqub N., Khalid S., Zhara T., Ansari S., Farzana T., Shamsi T.: Transplantation in low resource countries. *Thalassemia Reports* 1:30-33, 2011, doi:10.4081/thal.2011.s2.e9
34. Sodani P., Isgrò A., Gaziev J., Polchi P., Paciaroni K., Marziali M., Simone M.D., Roveda A., Montuoro A., Alfieri C., De Angelis G., Gallucci C., Erer B., Isacchi G., Zinno F., Adorno G., Lanti A., **Faulkner L.**, Testi M., Andreani M., and Lucarelli G.: Purified T-depleted, CD34+ peripheral blood and bone marrow cell transplantation from haploidentical mother to child with thalassemia. *Blood* 115 (6):1296-1302, 2010
35. Corrias M.V., Parodi S., Haupt R., Lacitignola L., Negri F., Sementa A.R., Dau D., Scuderi F., Carlini B., Bianchi M., Casale F., **Faulkner L.**, Garaventa A.. Detection of GD2 positive cells in bone marrow samples and survival of patients with localized neuroblastoma. *Br J Cancer*. 98 (2): 263-269, 2008.
36. Iannalfi A, Bambi F, Tintori V, Lacitignola L, Bernini G, Mariani MP, Sanvito MC, Pagliai F, Brandigi F, Muscarella E, Tapinassi F, and **Faulkner L.** Peripheral blood progenitor uncontrolled-rate freezing: a single pediatric center experience. *Transfusion*. 47 (12):2202-2206, 2007.
37. Corrias MV, **Faulkner LB**, Pistorio A, Rosanda C, Callea F, Piccolo MS, Scaruffi P, Marchi C, Lacitignola L, Occhino M, Gambini C, Tonini GP, Haupt R, De Bernardi B, Pistoia V, and Garaventa A. Detection of neuroblastoma cells in bone marrow and peripheral blood by different techniques: accuracy and relationship with clinical features of patients. *Clin.Cancer Res*. 10 (23):7978-7985, 2004.
38. Bambi F, Fontanazza S, Messeri A, Lippi A, Tucci F, Tamburini A, Tintori V, Casini T, Lacitignola L, Tondo A, Veltroni M, BerniniG , and **Faulkner LB.** Use of percutaneous radial artery catheter for peripheral blood progenitor cell collection in pediatric patients. *Transfusion* 43 (2):254-258, 2003.
39. Jayne D, Passweg J, Marmont A, Farge d, Khao X, Arnold R, Hiepe F, Lisukov I, Musso M, Ou-Yang J, Marsh J, Wulffraat N, Besalduch J, Bingham SJ, Emery P, Brune M, Fassas A, **Faulkner L**, Ferster A, Fiehn C, Fouillard I, Geromin A, Greinix H, Rabusin M, Saccardi R, Scheneider P, Zintl F, Gratwohl A,

- and Tyndall A. Autologous stem cell transplantation for Systemic Lupus Erythematosus. *Lupus* 13 (3):168-176, 2004.
40. Pagani A, Macri L, **Faulkner LB**, Tintori V, Paoli A, Garaventa A, and bussolanti G. Detection procedures for neuroblastoma cells metastatic to blood and bone marrow: blinded comparison of chromogranin A heminested reverse transcription polymerase chain reaction to tyrosine hydroxylase nested reverse transcription polymerase chain reaction and to anti-GD2 immunocytology. *Diagn.Mol.Pathol.* 11 (2):98-106, 2002.
 41. Sardi I, Tintori V, Marchi C, Veltroni M, Lippi A, Tucci F, Tamburini A, Bernini G, and **Faulkner L**. Molecular profiling of high-risk neuroblastoma by cDNA array. *Int.J Mol.Med* 9 (5):541-545, 2002.
 42. **Faulkner LB**, Garaventa A, Paoli A, Tintori V, Tamburini A, Lacitignola L, Veltroni M, Lo Piccolo MS, Viscardi E, Milanaccio C, Tondo A, Spinelli S, Bernini G, and De Bernardi B. *In vivo* cytoreduction studies and cell-sorting enhanced tumor cell detection in high-risk neuroblastoma patients: implications for leukapheresis strategies. *J Clin Oncol* 18(22):3829-3836 , 2000.
 43. Pession A, Rondelli R, Paolucci P, Pastore G, Dini G, Bonetti F, Madon E, Mandelli F, Zanesco L, Uderzo C, Prete A, Rabusin M, Ugazio A, Di Bartolomeo P, Favre C, **Faulkner L**, Poggi V, Luksch R, Donfrancesco A, Argiolu F, La Nasa G, Amici A, and Locatelli F. Hematopoietic stem cell transplantation in childhood: report from the bone marrow transplantation group of the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP). *Haematologica* 85(6):638-646, 2000.
 44. van den Oudenrijn S, Bruin M, Folman CC, Peters M, **Faulkner LB**, de Haas M, and von dem Borne AE. Mutations in the thrombopoietin receptor, Mpl, in children with congenital amegakaryocytic thrombocytopenia. *Br J Hematol* 110(2):441-448, 2000.
 45. Bambi F, **Faulkner LB**, Azzari C, Gelli AMG, Tamburini A, Tintori V, Lippi AA, Tucci F, Bernini G, Genovese F. Pediatric peripheral blood progenitor collection: Haemonetics MCS 3p vs COBE Spectra vs Fresenius AS 104. *Transfusion* 1998;38:70-74.
 46. **Faulkner LB**, Tucci F, Tamburini A, Tintori V, Lippi A, Bambi F, Malentacca F, Azzari C, Gelli AMG, Genovese F, Bernini G. G-CSF serum pharmacokinetics during peripheral blood progenitor cell mobilization: neutrophil count-adjusted dosage might potentially improve mobilization and be more cost-effective. *Bone Marrow Transplant* 1998;21:1091-1095.
 47. **Faulkner LB**, Tintori V, Tamburini A, Paoli A, Garaventa A, Viscardi E, Tucci F, Lippi A, De Bernardi B, Bernini G. High-sensitivity immunocytological analysis of concomitant blood and marrow tumor cell distribution in neuroblastoma. *J Hematother* 1998;7:361-366.
 48. **Faulkner LB**, Tamburini A, Tintori V, Paoli A, Tondo A, Bernini G, Medicina D, Brisigotti M, Corrias MV, Scaruffi P, Rosanda C, Lo Piccolo MS, Viscardi E, Milanaccio C, Garaventa A, De Bernardi B. Detection of minimal residual disease in bone marrow and peripheral blood in neuroblastoma. Prognostic and therapeutic implications. *Med Surg Ped* 1998;20:175-178.
 49. **Faulkner LB**, Lindsley KL, Kher U, Heller G, Black P, Finlay JL. High-dose chemotherapy with autologous marrow rescue for malignant brain tumors: analysis of the impact of prior chemotherapy and cranio-spinal radiation on hematopoietic recovery. *Bone Marrow Transplant* 1996;17:389-394.
 50. **Faulkner LB**, Hajdu SI, Kher U, La Quaglia M, Exelby PR, Heller G, Wollner N. Pediatric desmoid tumor: retrospective analysis of 63 cases. *J Clin Oncol* 1995;13:2813-2818.
 51. Pini G, **Faulkner LB**. Cerebellar involvement in hypomelanosis of Ito. *Neuropediatrics* 1995;26:208-210.
 52. **Faulkner LB**, Finlay JL. Towards a better definition of risk-group-tailored treatment in medulloblastoma. A review of seven reports on data obtained in the computerized tomographic imaging era. *Crit Rev Neurosurg* 1994;4:13-23.
 53. Gillio AP, **Faulkner LB**, Alter BP, Reilly L, Klafter R, Heller G, Young D, Lipton JM, Moore MAS, O'Reilly RJ. Successful treatment of Diamond-Blackfan anemia with interleukin 3. *Stem Cells* 1993;11 (suppl 2):123-130.

54. Gillio AP, **Faulkner LB**, Alter BP, Reilly L, Klafter R, Heller G, Young DC, Lipton JM, Moore MAS, O'Reilly RJ. Treatment of Diamond-Blackfan Anemia with recombinant human interleukin-3. *Blood* 1993;82:744-751.

Other recognitions

An entire chapter dedicated to Cure2Children on Nobel Prize Professor Muhammad Yunus's book "Building Social Business: The New Kind of Capitalism That Serves Humanity's Most Pressing Needs". Chapter 4: "To Cure One Child". 2010, ISBN 978-1-58648-824-6 (hardcover).